Collaboration and License Agreements - Additional Information (Details) $ in Thousands				3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 09, 2024 USD ($) engager	Feb. 21, 2024	Feb. 08, 2023	Sep. 30, 2024 USD ($)	Mar. 31, 2024 USD ($) pathogen	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 pathogen program	Dec. 31, 2020 program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development				$ 195,178		$ 145,028	$ 400,416	$ 470,754
Total revenues				2,380		2,639	61,831	69,393
Sanofi
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of oncology TCEs | engager	3
Upfront	$ 100,000
Milestone payment in escrow	75,000
Maximum future development and regulatory milestone payments	323,000
Maximum commercial net sales-based milestone payments	1,490,000
Payments for asset acquisitions	3,700
Transaction costs	$ 4,612
Assembled Workforce | Sanofi
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Useful life	5 years
Contract revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues				1,391		289	54,468	1,484
2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments to counterparty									$ 341,400
Research and development				1,000		6,100	6,500	18,600
2021 Collaboration Agreement | 2021 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of separate programs | program										3	3
Number of non-influenza target pathogens | pathogen										3
Preliminary Collaboration Agreement | 2020 GSK | Antibody Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of development costs			72.50%
2021 GSK Collaboration
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development				$ 200		$ 600	$ 700	$ 1,900
Percentage of share development costs		50.00%
Percentage of share profit and loss		50.00%
2021 GSK Collaboration | Contract revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of non-influenza target pathogens | pathogen					2
Total revenues					$ 51,700